Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Bolt Biotherapeutics, Inc. (BOLT) had Consolidated Net Income/Loss of $-7.24M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.03M |
|
$-7.24M |
|
-- |
|
$0.03M |
|
$7.63M |
|
$-7.60M |
|
$0.36M |
|
$-7.24M |
|
$-7.24M |
|
$-7.24M |
|
$-7.24M |
|
|
Consolidated Net Income/Loss |
$-7.24M |
$-7.24M |
|
$-7.60M |
|
$-7.44M |
|
1.68M |
|
1.68M |
|
$-4.31 |
|
$-4.31 |
|
| Balance Sheet Financials | |
$25.75M |
|
$1.04M |
|
$22.27M |
|
$48.03M |
|
$7.34M |
|
$19.35M |
|
$20.86M |
|
$28.20M |
|
$19.82M |
|
$19.82M |
|
$19.82M |
|
1.92M |
|
| Cash Flow Statement Financials | |
$-8.02M |
|
$7.92M |
|
$0.01M |
|
$13.44M |
|
$13.35M |
|
$-0.09M |
|
$0.55M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.51 |
|
-- |
|
-- |
|
0.49 |
|
0.98 |
|
100.00% |
|
-29234.61% |
|
-29234.61% |
|
-- |
|
-27861.54% |
|
-27861.54% |
|
$-7.99M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-36.55% |
|
-36.55% |
|
-15.08% |
|
-18.49% |
|
$10.31 |
|
$-4.76 |
|
$-4.78 |
|